Skip to content

Study · Animal study (in vivo) · 2026

12 results

[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].

de Souza-Lima J, Astrosa-Martin BD, Galaz-Rodríguez CA, Silva-Bernal JE, Orellana-Pizarro LI, Mena-Díaz CA

Revista medica de Chile1 Feb 2026

PMID42024694 (opens in a new tab)DOI10.4067/s0034-98872026000200237 (opens in a new tab)PepBankPUB-42024694
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In obesity models, SLU‑PP‑332 reduced adiposity.

    In plain wordsIn animal obesity models, SLU‑PP‑332 reduced body fat.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseAdiposity
    Study

    n: not reported in source

    Animal obesity models
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In obesity models, SLU‑PP‑332 improved glycemic control.

    In plain wordsIn animal obesity models, SLU‑PP‑332 improved blood sugar control.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseGlycemic control
    Study

    n: not reported in source

    Animal obesity models
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In obesity models, SLU‑PP‑332 increased basal energy expenditure.

    In plain wordsIn animal obesity models, SLU‑PP‑332 increased energy use at rest.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseBasal energy expenditure
    Study

    n: not reported in source

    Animal obesity models
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In obesity models, SLU‑PP‑332 showed no evident toxicity.

    In plain wordsIn animal obesity models, SLU‑PP‑332 showed no evident toxicity.

    Peptide
    SLU-PP-332
    Outcome
    Not applicableEvident toxicity
    Study

    n: not reported in source

    Animal obesity models
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In aging kidneys, SLU‑PP‑332 and SLU-PP-915 restored mitochondrial function.

    In plain wordsIn aging animal kidneys, SLU‑PP‑332 and SLU-PP-915 restored mitochondrial function.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseKidney mitochondrial function
    Study

    n: not reported in source

    Aging animal kidneys
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, they restore mitochondrial function and reduce inflammation in aging kidneys.
    2 context sentences
    Summary · context
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In aging kidneys, SLU‑PP‑332 and SLU-PP-915 reduced inflammation.

    In plain wordsIn aging animal kidneys, SLU‑PP‑332 and SLU-PP-915 reduced inflammation.

    Peptide
    SLU-PP-332
    Outcome
    DecreaseKidney inflammation
    Study

    n: not reported in source

    Aging animal kidneys
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, they restore mitochondrial function and reduce inflammation in aging kidneys.
    2 context sentences
    Summary · context
    SLU-PP-332 and SLU-PP-915 reduce adiposity, improve glycemic control, and increase basal energy expenditure in obesity models, without evident toxicity.
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

Studies that did not test the peptide alone6

In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking SLU-PP-332.

  1. 07AnimalNot a test of SLU-PP-332 aloneOther designMechanism

    In preclinical models, pan-ERR agonists induced an ERRα-dependent gene expression program like acute aerobic exercise.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, induced an exercise-like gene expression program dependent on ERRα.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseExercise-like gene expression program
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Pan-ERR agonists induce a gene expression program like acute aerobic exercise, dependent on ERRα, including activation of Ddit4 and Slc25a25.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

  2. 08AnimalNot a test of SLU-PP-332 aloneOther designMechanism

    In preclinical models, pan-ERR agonists activated Ddit4 within an ERRα-dependent exercise-like gene expression program.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, activated Ddit4.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseDdit4 activation
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Pan-ERR agonists induce a gene expression program like acute aerobic exercise, dependent on ERRα, including activation of Ddit4 and Slc25a25.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

  3. 09AnimalNot a test of SLU-PP-332 aloneOther designMechanism

    In preclinical models, pan-ERR agonists activated Slc25a25 within an ERRα-dependent exercise-like gene expression program.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, activated Slc25a25.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseSlc25a25 activation
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Pan-ERR agonists induce a gene expression program like acute aerobic exercise, dependent on ERRα, including activation of Ddit4 and Slc25a25.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

  4. 10AnimalNot a test of SLU-PP-332 aloneOther designMechanism

    In preclinical models, pan-ERR agonists enhanced fatty acid oxidation.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, increased fatty acid oxidation.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseFatty acid oxidation
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    They enhance fatty acid oxidation, increase type IIa muscle fibers (oxidative-glycolytic, with mixed substrate utilization including fatty acids and glucose), and improve endurance.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

  5. 11AnimalNot a test of SLU-PP-332 aloneOther designEfficacy outcome

    In preclinical models, pan-ERR agonists increased type IIa muscle fibers.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, increased type IIa muscle fibers.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseType IIa muscle fibers
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Exercise and physical function · Musculoskeletal

    Source sentences

    Summary
    They enhance fatty acid oxidation, increase type IIa muscle fibers (oxidative-glycolytic, with mixed substrate utilization including fatty acids and glucose), and improve endurance.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

  6. 12AnimalNot a test of SLU-PP-332 aloneOther designEfficacy outcome

    In preclinical models, pan-ERR agonists improved endurance.

    In plain wordsIn preclinical models, pan-ERR agonists, including SLU‑PP‑332, improved endurance.

    Peptide
    SLU-PP-332
    Outcome
    IncreaseEndurance
    Study

    n: not reported in source

    Preclinical animal and cell models
    Outcome group
    Exercise and physical function · Musculoskeletal

    Source sentences

    Summary
    They enhance fatty acid oxidation, increase type IIa muscle fibers (oxidative-glycolytic, with mixed substrate utilization including fatty acids and glucose), and improve endurance.
    1 context sentence
    Summary · context
    A systematic review of scientific literature from 2020 to 2024 was conducted, including experimental studies in animals and cell models.

    In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.